MSHLDaratumumab SC Solution For Injection 1,800 mg/15 mL
1) Daratumumab in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant.
2) Daratumumab in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
3) Daratumumab in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
4) Daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for an autologous stem cell transplant.
5) Daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for patients with previously untreated light chain (AL) amyloidosis. Treatment with daratumumab should be continued until disease progression or for a maximum of 24 cycles.